Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01631552 (Clinical Trial/ SACITUZUMAB GOVITECAN/ IMMU-132 / HRS7-SN38)

Study Title
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers (NCT01631552)

Trial Description

The primary objective is to evaluate the safety and tolerability of IMMU-132 as a single agent administered in 3-week treatment cycles for up to 8 cycles, in previously treated patients with advanced epithelial cancer.The secondary objectives are to obtain initial data concerning pharmacokinetics, immunogenicity, and efficacy with this dosing regimen. IMMU-132 targets the TROP-2 antigen which is expressed on a variety of cancers.

The antibody, RS7, is attached to SN38, which is the active metabolite of irinotecan. This is planned as a multi-center study. In Phase II, up to 130 patients (assessable) in triple-negative breast cancer, up to 100 patients (assessable) in non-small cell and small-cell lung cancer and up to 50 patients (assessable) per other cancer types included in the protocol will be studied at the 10 mg/kg dose.

This trial is sponsored by Immunomedics, Inc.

Study Data

  • Condition:
    • Colorectal Cancer
    • Gastric Adenocarcinoma
    • Esophageal Cancer
    • Hepatocellular Carcinoma
    • Non-small Cell Lung Cancer
    • Small Cell Lung Cancer
    • Ovarian Epithelial Cancer
    • Carcinoma Breast Stage IV
    • Hormone-refractory Prostate Cancer
    • Pancreatic Ductal Adenocarcinoma
    • Head and Neck Cancers- Squamous Cell
    • Renal Cell Cancer
    • Urinary Bladder Neoplasms
    • Cervical Cancer
    • Endometrial Cancer
    • Follicular Thyroid Cancer
    • Glioblastoma Multiforme
  • Interventions:
    • Drugs used in this trial
      • IMMU-132
  • Phase: I & II
  • Estimated Enrollment: 250
  • Start: February 2013
  • Estimated Completion: June 2016
  • Last verified: December 2015
  • Last updated: December 2015

Study Schematic

NCT01631552 (Clinical Trial/ SACITUZUMAB GOVITECAN/ IMMU-132 / HRS7-SN38)

Click here to Return to Drug map


Last Editorial review: November 9, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar